Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Life Technologies Acquires Compendia

By Drug Discovery Trends Editor | October 9, 2012

Life Technologies has announced the acquisition of Compendia Bioscience, a cancer bioinformatics company widely used by the pharmaceutical industry to identify novel gene targets for drug discovery and development. Its deep oncology expertise and high-value, proprietary assets enhance Life’s diagnostic development capabilities across multiple platforms, including next-generation sequencing, qPCR, and proteome analysis.

Compendia’s existing business, which will continue under the leadership of its current management team, adds an established base of pharmaceutical industry customers for Life Technologies’ platforms. Compendia’s oncology data is widely utilized by leading pharmaceutical companies in their drug development work and will extend Life’s abilities to both develop its own tests and to partner with pharmaceutical companies in companion diagnostic development.

“We have created the optimal foundation to drive progress in personalized medicine,” said Gregory T. Lucier, Chairman and Chief Executive Officer of Life Technologies. “By combining the acquisitions of Pinpoint Genomics, Navigenics and Compendia, we now possess the full spectrum capability to develop and commercialize high-value cancer diagnostics where there is currently great unmet need.”

The recent launch of Pervenio Lung RS, a first-of-its-kind prognostic test, underscores Life Technologies’ strategy to focus initially on lung cancer, a highly underserved disease. The company plans to utilize the extensive content in Compendia to springboard to other areas of oncology.

Date: October 8, 2012
Source: Life Technologies


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE